CIALIS - AN OVERVIEW

In Oct 2007, the FDA announced which the labeling for all PDE5 inhibitors, which include tadalafil, requires a much more prominent warning from the potential hazard of sudden Listening to loss as the result of publish-advertising reviews of short term deafness connected to use of PDE5 inhibitors.[19][8] The FDA concluded which they were not able to